CAJ | 학술논문

目的：观察消乳块胶囊对乳腺肿瘤模型大鼠血浆胰岛素样生长因子-1（IGF-1）水平的影响。方法64只50日龄SD健康雌性未孕大鼠随机分为模型组、治疗组各25只和对照组14只。模型组和治疗组大鼠均先经2次9，10-二甲基苯蒽（DMBA，15mg溶于1.5mL芝麻油，间隔1周）灌胃造模，同时治疗组大鼠以消乳块胶囊0.4g/（kg·d）灌胃，持续给药,在第11周和14周分批处死大鼠，取乳腺组织及肿瘤组织作常规病理检查，酶联免疫吸附法测定血浆IGF-1水平。结果与病理表现正常大鼠相比，乳腺癌变及增生大鼠血浆IGF-1水平升高明显[（138.65±8.54）ng/mL、（212.32±10.38）ng/mL比（97.70±5.16）ng/mL，P<0.01]，癌变大鼠增高更为明显，与增生大鼠相比，差异有统计学意义[（212.32±10.38）ng/mL比（138.65±8.54）ng/mL，P<0.05]。模型组、治疗组11、14周时血浆IGF-1较对照组明显增高[11周：（196.99±7.85）ng/mL、（142.33±8.62）ng/mL比（101.46±7.07）ng/mL， P<0.01；14周：（229.40±13.37）ng/mL、（138.75±8.82）ng/mL比（90.26±2.50）ng/mL，P<0.01]，治疗组11、14周血浆IGF-1水平较模型组有明显下降[11周：（142.23±8.62）ng/mL比（196.99±7.85）ng/mL， P<0.01；14周：（138.75±8.82）ng/mL比（229.40±13.37）ng/mL，P<0.01]。结论消乳块胶囊对DMBA诱导的大鼠乳腺恶性肿瘤具有部分预防作用，其机制可能是通过降低血浆IGF-1水平来实现。
목적：관찰소유괴효낭대유선종류모형대서혈장이도소양생장인자-1（IGF-1）수평적영향。방법64지50일령SD건강자성미잉대서수궤분위모형조、치료조각25지화대조조14지。모형조화치료조대서균선경2차9，10-이갑기분은（DMBA，15mg용우1.5mL지마유，간격1주）관위조모，동시치료조대서이소유괴효낭0.4g/（kg·d）관위，지속급약,재제11주화14주분비처사대서，취유선조직급종류조직작상규병리검사，매련면역흡부법측정혈장IGF-1수평。결과여병리표현정상대서상비，유선암변급증생대서혈장IGF-1수평승고명현[（138.65±8.54）ng/mL、（212.32±10.38）ng/mL비（97.70±5.16）ng/mL，P<0.01]，암변대서증고경위명현，여증생대서상비，차이유통계학의의[（212.32±10.38）ng/mL비（138.65±8.54）ng/mL，P<0.05]。모형조、치료조11、14주시혈장IGF-1교대조조명현증고[11주：（196.99±7.85）ng/mL、（142.33±8.62）ng/mL비（101.46±7.07）ng/mL， P<0.01；14주：（229.40±13.37）ng/mL、（138.75±8.82）ng/mL비（90.26±2.50）ng/mL，P<0.01]，치료조11、14주혈장IGF-1수평교모형조유명현하강[11주：（142.23±8.62）ng/mL비（196.99±7.85）ng/mL， P<0.01；14주：（138.75±8.82）ng/mL비（229.40±13.37）ng/mL，P<0.01]。결론소유괴효낭대DMBA유도적대서유선악성종류구유부분예방작용，기궤제가능시통과강저혈장IGF-1수평래실현。
Objective To investigate the anticancer effect of "Xiao Rukuai" capsule on plasma insulin-like growth factor-1 (IGF-1) in rats with mammary tumor. Methods Sixty-four 50-day-old female Sprague-Dawley rats were randomly divided into 3 groups: model group (n=25), therapy group (n=25), and control group (n=14). Model group and therapy group were given DMBA by intragastric administration (15mg in 1.5mL sesame oil, twice, one week in-terval). Rats in therapy group were given additonal "Xiao Rukuai" capsule [0.4g/(kg·d)]by intragastric administration. All rats were killed in 11th or 14th week. The breast tissue or neoplasma were observed by routine pathology. The plasma IGF-1 levels were detected by ELISA assay. Results Compared to normal group, the levels of IGF-1 were remarkably higher in the cancerous and hyperplastic group (138.65±8.54ng/mL and 212.32±10.38ng/mL vs 97.70±5.16ng/mL, P<0.01); a significant difference was found between cancerous group and hyperplasia group (212.32±10.38ng/mL vs 138.65±8.54ng/mL, P<0.01). At 11th and 14th week, the levels of IGF-1 in the plasma in model and therapy group were significantly higher than that in control group (at 11th week: 196.99±7.85ng/mL and 142.33±8.62ng/mL vs 101.46±7.07ng/mL; at 14th week: 229.40±13.37ng/mL and 138.75±8.82ng/mL vs 90.26±2.50ng/mL; all P<0.01). After "Xiao Rukuai" capsule treatment, the levels of IGF-1 reduced remarkably, with a significant difference compared to that in model group (at 11th week: 142.33±8.62ng/mL vs 196.99±7.85ng/mL; at 14th week: 138.75±8.82ng/mL vs 229.40±13.37ng/mL; all P<0.01). Conclusion The "Xiao Rukuai" capsule has partly effect on prevent-ing the mammary carcinogenesis induced by DMBA. The mechanism may be associated with regulating IGF-1 levels.